HDAC9 and renal cell carcinoma: In summary, we showed that HNHA had more potent anti-tumor activity than the established HDAC inhibitors SAHA and TSA with induction of apoptosis through expression of Bcl-2 and engagement of the mitochondrial pathway in RCC cells in vitro and in vivo.